Table 2.
Analysis of discrepant resultsa
| Category and patient no. | PFGE | SCRA | DL | Antibiotic profile | OpGen | Final assessment |
|---|---|---|---|---|---|---|
| Discrepant results | ||||||
| 1 | S | D | S | S | S | |
| 7 | S | D | S | S | S | S |
| 10 | D | D | S | S | D | D |
| 14 | S | S | S | Db | S | |
| 18 | D | S | S | D | D | D |
| 22 | D | D | S | S | D | D |
| 26 | S | S | S | Dc | S | |
| 29 | S | D | S | S | S | |
| 30 | D | S | D | D | D | |
| 35 | S | S | S | Dd | S | |
| Control | ||||||
| 27 | S | S | S | S | S | S |
| 36 | S | S | S | S | S | S |
a
S, strains from the patient are in the same group; D, strains from the patient are in different groups.
b
Only different for mupirocin.
c
Only different for erythromycin.
d
Only different for trimethoprim-sulfamethoxazole.